Clinical utility of Gallium 68 Prostate Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography (PET) imaging in patients with initial biochemical relapse following definitive surgery or radiotherapy for prostate carcinoma (PCa), to determine the sensitivity of 68Ga-PSMA imaging in the detection of PCa and using intention to treat analysis to assess change in management.

Sir Charles Gairdner Hospital0 个研究点目标入组 40 人开始时间: 2015年6月11日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Histologically confirmed prostate carcinoma
•Initial biochemical relapse following definitive treatment (Surgery or XRT) for prostate carcinoma or biochemical relapse at least 6 months following previous systemic (hormonal) treatment. (Biochemical relapse defined as PSA>0.2ng/mL at >6 weeks post radical prostatectomy or a PSA level 2 ng/mL above the previous PSA nadir measured >3 months after external beam radiotherapy-EBRT).
•Standard staging imaging, bone scan and abdominal CT, performed within 4 weeks of referral, showing no or oligometastatic disease. (Oligometastatic disease includes up to a maximum of four lesions.)
•No other active neoplastic disease
•Able to undergo study procedures / treatment
•Able to provide informed consent

发起方